Search for a trial

A Randomized, Open-Label Phase 2/3 Study Comparing Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone In Participants with Advanced Nonsmall Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy (COSTAR Lung)

This study has been transitioned to CTIS with ID 2023-507475-21-00 check the CTIS register for the current data. Primary objective:To evaluate the efficacy of cobolimab + dostarlimab + docetaxel relative to docetaxel alone in participants with…